The use of metformin in women with polycystic ovary syndrome: an updated review
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Purposes Polycystic ovary syndrome (PCOS) is a major cause of female infertility, being present in up to 20% of women of childbearing age. Insulin resistance (IR) plays an important role in the pathophysiology of PCOS; therefore, its treatment may benefit women with the syndrome. The main drug used for IR management is metformin (MT). We aim to review the literature on the use of metformin in women with PCOS.Methods Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases. The research was restricted to articles published in English. Initially, only published meta-analyses were included, in the absence of meta-analyzes, RCT and well-designed prospective studies were used.Results Metformin increases success rates and decreases complication rates when used as an adjunctive medication for ovulation induction during low complexity assisted reproduction treatments and during ovarian stimulation for in vitro fertilization in women with PCOS. Evidence about the effect of metformin on fetal and obstetric complication rates is conflicting. Metformin is associated with high incidence of gastrointestinal symptoms; however, serious adverse effects are rare and there is no evidence of teratogenicity.Conclusion For women with PCOS, metformin is a good adjunctive medication for ovulation induction/stimulation for high and low complexity assisted reproduction therapies. The adverse effects are mostly mild, and there is no risk of teratogenicity, but the risk of long-term complications for the offspring is not yet defined. High heterogeneity of the studies limits extrapolation of findings, and further research is needed to determine which women will benefit most from the medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the treatment of PCOS, metformin is the gold standard metabolic treatment [4, 10].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, hyperinsulinemia stimulates the androgen overproduction of ovarian theca cells [10].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“IR and compensatory hyperinsulinemia can, directly and indirectly, lead to irregular menstrual cycles and hyperandrogenism.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Higher insulin levels reduce the sex hormone binding globulin (SHBG) production of the liver.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduced SHBG levels lead to increased free testosterone levels worsening the symptoms of hyperandrogenism.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799 · cited 1×
“The prevalence of PCOS ranges from 2 to 26% of the women at reproductive age [1–3]; therefore, it is considered the most common endocrinopathy in women and a frequent cause of female infertility [2, 4].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501 · cited 1×
“The mechanisms of action of MT are not completely understood, but include reduction of the hepatic gluconeogenesis through its direct action on the liver cells [9].”
BackgroundCriteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358 · cited 1×
“Despite the recommendation to classify PCOS patients according to phenotypes, these women often present with mild signs and symptoms only [6].”
BackgroundMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Yildiz, B. O., Bozdag, G., Yapici, Z., Esinler, I., & Yarali, H. (2012) · Human Reproduction · doi:10.1093/humrep/des232 · Cited by 704 · cited 1×
“The prevalence of PCOS ranges from 2 to 26% of the women at reproductive age [1–3]; therefore, it is considered the most common endocrinopathy in women and a frequent cause of female infertility [2, 4].”
BackgroundGonadotrophin-releasing hormone antagonists for assisted reproductive technology
Al-Inany, H. G., Youssef, M. A., Ayeleke, R. O., Brown, J., Lam, W. S., & Broekmans, F. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001750.pub4 · Cited by 600
Azziz, R. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002698 · Cited by 573
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · cited 2×
“As strategies for decreasing AEs, prolonged-release presentations should be preferred, the medication should be taken on an empty stomach, and the dose should be scaled up to the maximum dose, usually 2000 mg/day, over a period of 4 to 6 weeks [29].”
BackgroundNaderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Clinical and Biochemical Features of Polycystic Ovarian Disease
Goldzieher, J. W., & Axelrod, L. R. (1963) · Fertility and Sterility · doi:10.1016/s0015-0282(16)35047-6 · Cited by 283 · cited 2×
“Oligomenorrhea or anovulation are the most frequent findings of PCOS, affecting up to 74% of the women [5].”
BackgroundAdiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis
Toulis, K. A., Goulis, D. G., Farmakiotis, D., Georgopoulos, N. A., Katsikis, I., Tarlatzis, B. C., Papadimas, I., & Panidis, D. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp006 · Cited by 262 · cited 1×
“Moreover, the adipose tissue of women with PCOS contribute to IR due to adipocytokine dysfunction, decreased secretion of adiponectin, dysregulation of free fatty acid metabolism, and epigenetic abnormalities that affect the function of the glucose transporter 4, an important regulator of insulin sensibility [3, 8].”
BackgroundNaderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 255
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
Tso, L. O., Costello, M. F., Albuquerque, L. E. T., Andriolo, R. B., & Macedo, C. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006105.pub3 · Cited by 228
Jakubowicz, D. J., Seppälä, M., Jakubowicz, S., Rodriguez-Armas, O., Rivas-Santiago, A., Koistinen, H., Koistinen, R., & Nestler, J. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7295 · Cited by 164
Cassina, M., Donà, M., Di Gianantonio, E., Litta, P., & Clementi, M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu022 · Cited by 143
Wang, R., Li, W., Bordewijk, E. M., Legro, R. S., Zhang, H., Wu, X., Gao, J., Morin-Papunen, L., Homburg, R., König, T. E., et al. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz029 · Cited by 137 · cited 1×
“Another MA from a different group was performed using individual participant data from RCTs [13].”
MethodHanem, L. G. E., Salvesen, Ø., Juliusson, P. B., Carlsen, S. M., Nossum, M. C. F., Vaage, M. Ø., Ødegård, R., & Vanky, E. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30385-7 · Cited by 134 · cited 1×
“showed that these children displayed slightly higher mean BMI, higher body fat percentage, and higher prevalence of obesity when compared to the placebo group at 5–10 years of follow-up [34].”
BackgroundMetformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Sharpe, A., Morley, L. C., Tang, T., Norman, R. J., & Balen, A. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013505 · Cited by 132 · cited 4×
“The same trend appeared when the incidence of AE was compared between the combination of MT and CC versus CC alone, with higher incidence in the MT plus CC group, especially in the nonobese group [12].”
BackgroundInfluentialJakubowicz, D. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1126 · Cited by 130
Palomba, S., Pasquali, R., Orio, F., & Nestler, J. E. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03369.x · Cited by 100 · cited 1×
“Few studies have reported the incidence AE in patients with PCOS, with only 3 MAs reporting quantitative data [12, 19, 28].”
BackgroundWu, Y., Tu, M., Huang, Y., Liu, Y., & Zhang, D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11995 · Cited by 87
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome
Tso, L. O., Costello, M. F., Albuquerque, L. E. T., Andriolo, R. B., & Macedo, C. R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006105.pub4 · Cited by 83 · cited 3×
“In this context, a recent Cochrane MA assessed the results of 13 RCTs, including 10 studies with long GnRH-agonist protocols, and 3 studies using short GnRH-antagonist protocols [19].”
BackgroundMisso, M. L., Costello, M. F., Garrubba, M., Wong, J., Hart, R., Rombauts, L., Melder, A. M., Norman, R. J., & Teede, H. J. (2013) · Human Reproduction Update · doi:10.1093/humupd/dms036 · Cited by 81
Palomba, S., Falbo, A., & La Sala, G. B. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-3 · Cited by 78 · cited 2×
“44, I2 = 30%) with the combination therapy [16].”
BackgroundEffects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis
Zeng, X.-L., Zhang, Y.-F., Tian, Q., Xue, Y., & An, R.-F. (2016) · Medicine · doi:10.1097/md.0000000000004526 · Cited by 76 · cited 12×
“Both MAs included studies with moderate to high risk of bias; therefore, their results should be taken with caution.”
BackgroundResultInfluentialMeta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?
Pundir, J., Sunkara, S. K., El‐Toukhy, T., & Khalaf, Y. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2011.09.017 · Cited by 75
Kim, C. H., Chon, S. J., & Lee, S. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-64776-w · Cited by 73 · cited 1×
“The most recent MA regarding this topic included 13 prospective studies and assessed menstrual cycle frequency, as a surrogate for ovulation induction, and pregnancy rate [17].”
BackgroundOvarian enzyme activities in women with polycystic ovary syndrome
Magoffin, D. A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.03.015 · Cited by 64 · cited 1×
“Hyperandrogenism, the main metabolic disorder of PCOS, is a consequence of excessive production of dehydroepiandrosterone and androstenedione by the teca cells and the adrenal glands [7].”
BackgroundZhuo, Z., Wang, A., & Yu, H. (2014) · Journal of Diabetes Research · doi:10.1155/2014/381231 · Cited by 55
Wang, J., Zhu, L., Hu, K., Tang, Y., Zeng, X., Liu, J., & Xu, J. (2017) · Medicine · doi:10.1097/md.0000000000008183 · Cited by 52 · cited 1×
“Similarly, two MAs that assessed the use of MT in nonpregnant women with PCOS showed that its use improved clinical parameters such as BMI, waist-hip ratio, and diastolic blood pressure, but without impact on metabolic parameters and endocrine disorders [26, 27].”
BackgroundTan, X., Li, S., Chang, Y., Fang, C., Liu, H., Zhang, X., & Wang, Y. (2016) · Clinical and Investigative Medicine · doi:10.25011/cim.v39i4.27091 · Cited by 51 · cited 11×
“Both MAs included studies with moderate to high risk of bias; therefore, their results should be taken with caution.”
BackgroundResultInfluentialMetformin alters insulin signaling and viability of human granulosa cells
Sonntag, B., Götte, M., Wülfing, P., Schüring, A. N., Kiesel, L., & Greb, R. R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.04.043 · Cited by 48 · cited 1×
“Moreover, in vitro studies using human and other mammalian germ cells have shown that MT is able to regulate androgens and estradiol production as well as follicular recruitment [10, 11].”
BackgroundPatel, R., & Shah, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279597 · Cited by 47 · cited 1×
“Similarly, two MAs that assessed the use of MT in nonpregnant women with PCOS showed that its use improved clinical parameters such as BMI, waist-hip ratio, and diastolic blood pressure, but without impact on metabolic parameters and endocrine disorders [26, 27].”
BackgroundFetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS
Hjorth-Hansen, A., Salvesen, Ø., Engen Hanem, L. G., Eggebø, T., Salvesen, K. Å., Vanky, E., & Ødegård, R. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01191 · Cited by 47 · cited 1×
“Although the use of MT is not associated with increased risk of malformations [30–32], a Norwegian group longitudinally assessed the development of children whose mothers had PCOS and used MT during pregnancy [33].”
BackgroundXiong, F., Xiao, J., Bai, Y., Zhang, Y., Li, Q., & Lishuang, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.128 · Cited by 43
Hashim, H. A., Foda, O., & Ghayaty, E. (2015) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12673 · Cited by 42
Zhao, J., Liu, X., & Zhang, W. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0603-3394 · Cited by 31
Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study
Scherneck, S., Schlinke, N., Beck, E., Grupe, K., Weber-Schoendorfer, C., & Schaefer, C. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.07.004 · Cited by 28
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Underdal, M. O., Stridsklev, S., Oppen, I. H., Høgetveit, K., Andersen, M., & Vanky, E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00485 · Cited by 21 · cited 1×
“Moreover, a long-term study demonstrated that the use of MT during pregnancy only was not able to improve the BMI and metabolic profile of women with PCOS in the postpartum period [25].”
BackgroundMetformin has a direct effect on ovarian cells that is dependent on organic cation transporters
Pietro, M. D., Velázquez, C., Matzkin, M. E., Frungieri, M. B., Peña, M. G., de Zúñiga, I., Pascuali, N., Irusta, G., Bianchi, M. S., Parborell, F., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110591 · Cited by 20
The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome
Dragamestianos, C., Messini, C. I., Antonakis, P. T., Zacharouli, K., Kostopoulou, E., Makrigiannakis, A., Georgoulias, P., Anifandis, G., Dafopoulos, K. C., Garas, A., et al. (2018) · Gynecologic and Obstetric Investigation · doi:10.1159/000491086 · Cited by 14
Diav‐Citrin, O., Steinmetz-Shoob, S., Shechtman, S., & Ornoy, A. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.05.007 · Cited by 12
Mao, W., Zhang, S., Wang, L., & Shen, S. (2021) · Medicine · doi:10.1097/md.0000000000023954 · Cited by 3
Cited by
Kunnumakkara, A. B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U. D., Garodia, P., Yenisetti, S. C., Oommen, O. V., & Aggarwal, B. B. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00012 · Cited by 201
Fiorentino, G., Cimadomo, D., Innocenti, F., Soscia, D., Vaiarelli, A., Ubaldi, F. M., Gennarelli, G., Garagna, S., Rienzi, L., & Zuccotti, M. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmac031 · Cited by 176
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“In addition, hyperinsulinemia stimulates the androgen overproduction of ovarian theca cells [10].”
BackgroundMetformin role in Parkinson’s disease: a double-sword effect
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., Jabir, M. S., Negm, W. A., & Batiha, G. E. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04771-7 · Cited by 109
“Metformin increases success rates and decreases complication rates when used as an adjunctive medication for ovulation induction during low complexity assisted reproduction treatments and during ovarian stimulation for in vitro fertilization in women with PCOS [46].”
Sanchez-Garrido, M. A., Serrano-López, V., Ruíz-Pino, F., Vazquez, M. J., Rodríguez-Martín, A., Torres, E., Velasco, I., Rodríguez, A., Chicano‐Gálvez, E., Mora-Ortiz, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52898-y · Cited by 60
“Specific comments along these lines have been added to the revised paper (see page 16, lines 432-441).”
Metadata
- Authors
- Notaro, A. L. G., & Neto, F. T. L.
- Venue
- Journal of Assisted Reproduction and Genetics
- Published
- 2022-02-14
- Volume
- 39
- Issue
- 3
- Pages
- 573-579
- ISSN
- 0740-7769 (ISSN-L)
- 1058-0468
- 1573-7330
- PMC
- PMC8995234
- OpenAlex
- W4212921576
- Cited by
- 83
- References
- 48
- Citations by year
- 2026: 19 · 2025: 18 · 2024: 26 · 2023: 16 · 2022: 4
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Assisted Reproduction and Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- metformin, polycystic ovary syndrome, insulin resistance, ovulation induction, in vitro fertilization, assisted reproduction, female infertility, teratogenicity, gastrointestinal adverse effects
- MeSH terms
- Clomiphene, Female, Fertility Agents, Female, Humans, Hypoglycemic Agents, Infertility, Female, Insulin Resistance, Metformin, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy, Prospective Studies, Pregnancy Rate, Live Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.